Determination of CEM-101 activity tested against clinical isolates of Neisseria meningitidis from a worldwide collection.

Antimicrobial Agents and Chemotherapy
D J BiedenbachRonald N Jones

Abstract

The activity of CEM-101, a fluoroketolide, was compared to those of 11 other antimicrobial agents using the reference broth microdilution method tested against 103 Neisseria meningitidis strains, including ciprofloxacin-nonsusceptible isolates with confirmed gyrA (T91I) mutations. Among the tested isolates, 79.6% were serogroup B or C and all isolates were susceptible to ceftriaxone, azithromycin, minocycline, and rifampin. However, penicillin-nonsusceptible strains were observed (15.5%) and susceptibility to trimethoprim-sulfamethoxazole was only 50.5%. CEM-101 was the most active macrolide-like compound (MIC(90), < or = 0.015 microg/ml) compared with MIC(90)s of telithromycin (MIC(90), 0.03 microg/ml), azithromycin and clarithromycin (MIC(90), 0.12 microg/ml), and erythromycin (MIC(90), 0.25 microg/ml). CEM-101 could provide a potent alternative for the prophylaxis of meningococcal disease.

References

Mar 10, 1975·JAMA : the Journal of the American Medical Association·M S Artenstein
Jan 1, 1997·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·B A Oppenheim
Oct 21, 1998·The Pediatric Infectious Disease Journal·N GirgisA Mateczun
Sep 18, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Aude AntignacMuhamed-Kheir Taha
Nov 26, 2003·Antimicrobial Agents and Chemotherapy·Sydney CousinMarilyn C Roberts
Jan 20, 2004·The Journal of Antimicrobial Chemotherapy·B AlcaláJ de Batlle
Feb 25, 2005·The Journal of Antimicrobial Chemotherapy·Alejandra CorsoMarcelo Galas
Apr 28, 2005·Antimicrobial Agents and Chemotherapy·Tiffany R ShultzJohn W Tapsall
Sep 29, 2006·Journal of Clinical Microbiology·Vikas Manchanda, P Bhalla
Apr 6, 2007·International Journal of Antimicrobial Agents·Y W ChuK K Wong
Nov 23, 2007·The Journal of Antimicrobial Chemotherapy·Rocío EnríquezJulio A Vázquez
Aug 6, 2008·Emerging Infectious Diseases·Anna SkoczynskaMuhamed-Kheir Taha
Feb 24, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Don WeissUNKNOWN New York City Meningococcal Investigation Team
Feb 28, 2009·The New England Journal of Medicine·Henry M WuRuth Lynfield
Nov 7, 2009·Emerging Infectious Diseases·Giuseppe LapadulaAndrea Gori

❮ Previous
Next ❯

Citations

Feb 24, 2011·Expert Review of Anti-infective Therapy·Timothy R Walsh, Mark A Toleman
Feb 12, 2011·Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics·Gordon RamageJeremy Bagg
Mar 5, 2011·The Lancet Infectious Diseases·David M LivermoreNeil Woodford
Dec 24, 2011·Annals of the New York Academy of Sciences·Joyce A Sutcliffe
Apr 23, 2017·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Michael J BuegeSamuel L Aitken

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.